EASL has launched several highly influential Clinical Practice Guidelines (CPGs). The objective of these CPGs is to provide simple, clear, and evidence-based guidelines that can be used for patient management and reimbursement policies all over Europe. EASL CPGs have become…
ClarivateTM Analytics released the 2022 update of its Journal Citation Reports©, including the much anticipated 2021 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2021 impact factor of 30.083, up from the 2020…
1 June 2022 EASL is proud to announce the release of EASL Clinical Practice Guidelines on Haemochromatosis, just published in the Journal of Hepatology. This marks World Haemochromatosis Week taking place every year in the first week of June.
7 April 2022 On World Health Day, EASL explores the complex relationship between the well-being of the planet and that of our livers.
15 March 2022 EASL is proud to announce the release of new set of EASL Clinical Practice Guidelines (CPGs) on the prevention and management of bleeding and thrombosis in patients with cirrhosis, addressing the difficult clinical questions posed by the…
Scientists advocate for education programmes to raise awareness and improve early diagnosis, survival, and quality of life of cholangiocarcinoma (CCA) patients in the largest and most complete multicentre study of CCA, published in the Journal of Hepatology. Amsterdam, February 12,…
A large-scale epidemiologic study in China has identified links between long-term exposure to ambient air pollution and metabolic-associated fatty liver disease (MAFLD), report scientists in the Journal of Hepatology. Amsterdam, December 6, 2021 – Metabolic-associated fatty liver disease (MAFLD) is a growing…
ClarivateTM Analytics released the 2021 update of its Journal Citation Reports©, including the much anticipated 2020 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2020 impact factor of 25.083, up from the 2019…
An international study led by researchers at Oxford University Hospitals NHS Foundation Trust has shown that patients with cirrhosis are at increased risk of dying as a result of COVID-19. Oxford, October 6, 2020 – The study, published in the…
Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a new study from Karolinska Institutet in Sweden published in the Journal of Hepatology. The risk of…
